REVIEWS

2765 Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis
Sandeepa M. Eswarappa and Paul L. Fox

2770 Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic
Elizabeth R. Tucker, Laura S. Danielson, Paolo Innocenti, and Louis Chesler

MICROENVIRONMENT AND IMMUNOLOGY

2775 Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes
Cristina Ghirelli, Fabien Reyal, Marine Jeanmougin, Raphael Zollinger, Phílémon Sirven, Paula Michea, Christophe Caux, Nathalie Bendriuss-Vernare, Marie-Hélène Donnadieu, Martial Caly, Virginie Fourchotte, Anne Vincent-Salomon, Brigitte Sigal-Zafrani, Xavier Sastre-Garau, and Vassili Soumelis
Précis: This study describes a mechanism through which an aggressive breast cancer activates pDC to promote a regulatory Th2 response, with implications for therapeutic targeting of a tumor-immune axis of growing recognition in its significance to malignancy.

2788 NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay
Précis: NOS inhibition has long been studied in cancer to limited impact, but these new preclinical results show how inhibiting NOS in patients after they undergo radiotherapy can relieve immune escape in the tumor microenvironment and greatly improve treatment responses.

2800 Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells

Précis: This report identifies a stromal cell population expressing the fibroblast activation protein (FAP), which is required for the desmoplastic response seen in many human carcinomas, also showing how FAP-expressing cells promote tumor growth via immune suppression and immune-independent remodeling of the stromal microenvironment.

2811 Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity
Ashley Browne, Laura A. Tookman, Carin K. Ingemarsdotter, Russell D. Bouwman, Katrina Pirlo, Yaohe Wang, Iain A. McNeish, and Michelle Lockley
Précis: This work describes a novel and clinically feasible strategy to facilitate the safe delivery of systemic viral anticancer therapies by using clinically available β3 integrin inhibitors to control the problematic inflammatory side effects induced by these effective anticancer agents.

2822 Definition of Prostaglandin E2–EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth
Xiaojun Ma, Tomohiro Aoki, Tatsuaki Tsuruyama, and Shuh Narumiya
Précis: These findings show how prostaglandin signaling in neutrophils and cancer-associated fibroblasts in the colorectal tumor microenvironment shape its inflammatory character, providing a mechanistic rationale to use EP2 antagonists as an alternative to aspirin for chemoprevention.
MOLECULAR AND CELLULAR PATHOBIOLOGY

2833  TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor–Binding Sites in Chronic Myelomonocytic Leukemia
Jumpei Yamazaki, Jaroslav Jelinek, Yue Lu, Matteo Cesaroni, Jozef Madzo, Frank Neumann, Rong He, Rodolphe Taby, Aparna Vasanthakumar, Trisha Macrae, Kelly R. Ostler, Hagop M. Kantarjian, Shoushan Liang, Marcos R. Estacio, Lucy A. Godley, and Jean-Pierre J. Issa
Précis: Results show how mutations in a leukemia-associated gene act epigenetically by influencing the DNA methylation of hematopoietic-specific enhancers that affect leukemia development.

PREVENTION AND EPIDEMIOLOGY

2844  Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer
Alina Lemnrau, Mark N. Brook, Olivia Fletcher, Penny Coulson, Katarzyna Tomczyk, Michael Jones, Alan Ashworth, Anthony Swerdlow, Nick Orr, and Montserrat Garcia-Closas
Précis: The use of mtDNA copy number measured in blood samples prior to diagnosis is associated with elevated risk of developing breast cancer.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

2851  Enhanced MET Translation and Signaling Sustains K-Ras–Driven Proliferation under Anchorage-Independent Growth Conditions
Saori Fujita-Sato, Jacqueline Gales, Morgan Truitt, Cameron Pitt, Anatoly Urisman, Sourav Bandopadhayay, Davide Ruggiero, and Frank McCormick
Précis: These results suggest that to drive malignant cell growth K-Ras requires the activity of the Met receptor kinase, a therapeutic target already being explored in the clinic, with implications in addressing the long-standing challenge of how to attack K-Ras–driven human tumors.

2863  Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer
Lina S. Schneider, Karin von Schwarzenberg, Thorsten Leht, Melanie Ulrich, Rebekka Kubiach-Dohmen, Johanna Liebl, Dirk Trauner, Dirk Menche, and Angelika M. Vollmar
Précis: Inhibition of a vacuolar ATPase that functions as an ion pump in maintaining cellular metabolic pathways in cancer appears to selectively disturb iron metabolic pathways, thereby blocking tumor growth.

2875  An In Vivo Method to Identify microRNA Targets Not Predicted by Computation Algorithms: p21 Targeting by miR-92a in Cancer
Xiaoping Su, Huaming Wang, Wei Ge, Mingin Yang, Jin Hou, Taojong Chen, Nan Li, and Xuetao Cao
Précis: This study describes a new method for in vivo miRNA precipitation (miRIP), which can identify target-specific miRNAs for an mRNA not otherwise identified by current in silico methods.

2886  Secalonic Acid-D Represses HIF1α/VEGF-Mediated Angiogenesis by Regulating the Akt/mTOR/p70S6K Signaling Cascade
Précis: These findings offer a preclinical validation of the antiangiogenic uses for a novel mycotoxin in the generalized treatment of solid tumors.
TUMOR AND STEM CELL BIOLOGY

2937 Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma
Colleen L. Doçi, Constantinos M. Mikelis, Michael S. Lionakis, Alfredo A. Molinolo, and J. Silvio Gutkind

Précis: By focusing on recurrent 3p21 deletions in head and neck cancers, this study identifies a novel metastasis suppressor gene that offers an appealing prognostic biomarker and therapeutic target in this setting.

2949 Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis
Chun-Jung Ko, Cheng-Chung Huang, Hsin-Ying Lin, Chun-Pai Juan, Shuo-Wei Lan, Hsin-Yi Shyu, Shang-Ru Wu, Pei-Wen Hsiao, Hsiang-Po Huang, Chia-Tung Shun, and Ming-Shyue Lee

Précis: This important study shows how the serine protease TMPRSS2 promotes the growth, invasion, and metastasis of prostate cancer cells via activation of the matrix protease matriptase, with implications that targeting these two proteases may offer new options to treat advanced prostate cancer.

2916 Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALKþ Tumors

Précis: This important study shows how kinase upregulation in cancer cells can foster resistance to a kinase inhibitory drug, but that this upregulation also sensitizes cells to kinase-mediated toxicities that can be exploited by altering the drug dosing schedule, as a strategy to defeat the drug resistance.

2928 Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti–PD-L1 Antibodies
Sandra Heskamp, Willemijn Hobo, Janneke D.M. Molkenboer-Kuenen, Daniel Olive, Wim J.G. Oyen, Harry Dolstra, and Otto C. Boerman

Précis: PD-L1 expression in tumors is important for PD-1/PD-L1–based therapeutics and can be monitored noninvasively using SPECT/CT imaging, which may more readily enable patient selection for trials of this type of antibody-based immune checkpoint therapy.

Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/75/14

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.